Patienterne bør monitoreres nøje for at sikre, at den lavest godkendte dosis af NeoRecormon anvendes til at sørge for tilstrækkelig kontrol af de anæmiske symptomer.
Patients should be monitored closely to ensure that the lowest approved dose of NeoRecormon is used to provide adequate control of the symptoms of anaemia.